Alnylam

Wool heart
Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Glowing puzzle piece fitting into puzzle

Alnylam pays Inceptive $30M to transform siRNA design

Jun 4, 2026 4:13am
Lifeline

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm
heart over ekg

Corsera launches with $50M for predictive AI tool, RNAi asset

Sep 2, 2025 6:30am
Businessman climbing steps to pluck a star from the sky

Regeneron posts phase 3 win, advancing push to muscle in on gMG

Aug 26, 2025 9:41am
heart monitor

BridgeBio touts extension study data for ATTR-CM drug acoramidis

Nov 18, 2024 3:38pm